GU Cancers 2024 | Enfortumab vedotin as monotherapy in heavily pretreated mCRPC

Umang Swami, MD, MS, University of Utah, Salt Lake City, UT, gives an overview of a Phase II trial (NCT04754191) of enfortumab vedotin (EV), an antibody-drug conjugate (ADC) in heavily-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). The primary objective was antitumor activity and in stage I of the trial, 11 patients were treated, with promising responses and manageable adverse events recorded. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.